Jade Biosciences (JBIO) Accumulated Expenses (2020 - 2026)

Jade Biosciences (JBIO) has 7 years of Accumulated Expenses data on file, last reported at $14.9 million in Q1 2026.

• Quarterly Accumulated Expenses rose 629.47% year-over-year to $14.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $14.9 million (up 629.47% YoY) and the FY2025 annual result came in at $9.4 million, up 128.34% from the prior year.
• Accumulated Expenses climbed to $14.9 million in Q1 2026, from $9.4 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $14.9 million in Q1 2026 to a low of $817000.0 in Q2 2022.
• A 5-year average of $7.1 million and a median of $7.7 million in 2023 frame the typical range for Accumulated Expenses.
• Annual changes were most pronounced in 2023 — Accumulated Expenses surged 802.82% — and 2025, when it plunged 79.12%.
• Tracing JBIO's Accumulated Expenses over 5 years: stood at $2.8 million in 2022, then surged by 240.35% to $9.4 million in 2023, then tumbled by 55.94% to $4.1 million in 2024, then jumped by 128.34% to $9.4 million in 2025, then soared by 57.68% to $14.9 million in 2026.
• The last three Accumulated Expenses figures came in at $14.9 million (Q1 2026), $9.4 million (Q4 2025), and $14.0 million (Q3 2025), per Business Quant data.